CerFlux
- Biotech or pharma, therapeutic R&D
- Medical device or technology
- Synthesis, analytic, diagnostic services
CerFlux high-throughput PEER technology matches your oncology drug candidates to patient-derived and mechanism-specific cell-line 3D tumor models to accelerate development and strengthen licensing positions. Our platform recreates human tumor microenvironments, identifying responders vs. non-responders in weeks rather than months. We help partners de-risk preclinical assets, optimize formulations, make informed go/no-go decisions earlier, accelerate IND filings, and build stronger regulatory submissions. Partner with CerFlux to reduce costs, minimize animal testing, and optimize your oncology pipeline with predictive insights that matter to regulators and patients alike.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}